Feldan Therapeutics

Feldan Therapeutics is a clinical-stage biotech company that specializes in the development of treatments based on the intracellular delivery of therapeutics. It has developed the Feldan Shuttle®, a proprietary peptide-based technology for delivering antisense oligonucleotides to cells. The company is conducting a Phase 1 clinical trial of FLD-103 for basal cell carcinoma and advancing FLD-201 for respiratory diseases.

Feldan Therapeutics is a clinical-stage biotech company that specializes in the development of treatments based on the intracellular delivery of therapeutics. It has developed the Feldan Shuttle®, a proprietary peptide-based technology that enables safe, rapid, and efficient delivery of antisense oligonucleotides (ASO) to cells. The company is conducting a Phase 1 clinical trial of FLD-103, an investigational non-surgical treatment for basal cell carcinoma (BCC), across multiple clinical sites in the United States and Australia. In Australia, the trial is overseen by Feldan's wholly owned subsidiary, Feldan Australia Pty Ltd. Feldan is also advancing FLD-201, an inhaled investigational therapy for mucus-driven respiratory diseases, including non-cystic fibrosis bronchiectasis (NCFB) and chronic bronchitis, currently in preclinical development.

• Feldan Shuttle®

  A proprietary peptide-based technology that enables safe, rapid, and efficient delivery of antisense oligonucleotides (ASO) to cells.

• FLD-103

  An investigational non-surgical treatment for basal cell carcinoma (BCC), currently in Phase 1 clinical trial.

• FLD-201

  An inhaled investigational therapy for mucus-driven respiratory diseases, including non-cystic fibrosis bronchiectasis (NCFB) and chronic bronchitis, currently in preclinical development.

1. 1Feldan Therapeutics - Therapeutics where they matterfeldan.com
2. 2Feldan Therapeutics - Aboutfeldan.com
3. 3Feldan Therapeuticswikidata.org